HM Payson & Co’s United Therapeutics UTHR Stock Holding History

HM Payson & Co’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8	Closed	-$1K	–	1145
2022 Q1	$1K	Buy	+8	New	+$1.52K	﹤0.01%	1034

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

HM Payson & Co's UTHR Position: Q2 2022 in Review

HM Payson & Co sold out of United Therapeutics (UTHR) in Q2 2022, closing a stake of 8 shares — an estimated $1K sold.

HM Payson & Co first reported a position in UTHR in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 472 funds tracked by Wall St. Rank hold UTHR as of Q2 2022.

HM Payson & Co reported no remaining United Therapeutics position as of Q2 2022 after selling out during the quarter.
HM Payson & Co sold 8 United Therapeutics shares in Q2 2022, an estimated $1K.
HM Payson & Co first reported a position in United Therapeutics in Q1 2022 and held it in 1 quarter.
HM Payson & Co's United Therapeutics position peaked at $1K in Q1 2022.
472 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2022.

Based on HM Payson & Co's 13F filing for Q2 2022, filed 15 Aug 2022.